#biotech

📰News 📈 Stocks

Latigo Prices IPO at $345.6 Million, Debuts as Non-Opioid Pain Drug Developer

August 7, 2026 (50 days ago)

Latigo's $345.6 million IPO highlights Wall Street's bet on non-opioid pain therapies, marking a significant entry for the biotech firm into public…

LTGO

🌍 US Read More →

📰News 📈 Stocks

Braveheart Bio Jumps 68% in Debut After $382.5 Million IPO Backed by A16z

August 6, 2026 (50 days ago)

Braveheart Bio (BRAV) stock price soars 68% on IPO day after a $382.5 million offering backed by A16z, signaling strong demand for…

BRAV XBI

🌍 US Read More →

📰News 📈 Stocks

Braveheart Biotech Prices $382.5 Million Upsized IPO, Signaling Strong Demand

August 6, 2026 (51 days ago)

Braveheart Biotech's $382.5 million upsized IPO underscores robust demand for biotech offerings and may boost sector ETFs like IBB.

BRAVEHEART IBB

🌍 US Read More →

📰News 📋 Bonds

AbbVie Plans $10 Billion Bond Sale to Finance Apogee Therapeutics Acquisition

August 4, 2026 (52 days ago)

AbbVie launches a $10 billion bond offering to finance the Apogee Therapeutics deal, marking a major pharmaceutical M&A debt issuance in 2026.

APGE ABBV LQD

🌍 US Read More →

📰News 📈 Stocks

Latigo Biotech Files for $288M Nasdaq IPO to Fund Non-Opioid Pain Drugs

August 3, 2026 (53 days ago)

Latigo files for $288M US IPO to advance its non-opioid painkiller pipeline, capitalizing on strong investor interest in safer alternatives to addictive…

NDX

🌍 US Read More →

📰News 📈 Stocks

Apnimed Stock Soars 38% in Debut After Upsized US IPO

July 31, 2026 (56 days ago)

Sleep-apnea biotech Apnimed's stock jumped 38% in its NYSE debut following an upsized US IPO that exceeded initial targets, underscoring strong investor…

APNM

🌍 US Read More →

📰News 📈 Stocks

Goldman-Backed Biotech Attovia Seeks $212.5M in Nasdaq IPO

July 30, 2026 (58 days ago)

Goldman Sachs-backed biotech firm Attovia is seeking $212.5 million in a US IPO, signaling ongoing appetite for healthcare listings amid cautious equity…

GS

🌍 US Read More →

📰News 📈 Stocks

Apnimed Aims to Raise $160 Million in US IPO With Shionogi Backing

July 28, 2026 (59 days ago)

Shionogi-backed biotech Apnimed seeks to raise $160 million in a US IPO, highlighting investor appetite for sleep disorder treatments and cross-border healthcare…

4507

🌍 US Read More →

📰News 📈 Stocks

Eli Lilly-Backed Scribe Therapeutics Soars 50% After Upsized IPO

July 24, 2026 (63 days ago)

Eli Lilly-backed biotech Scribe Therapeutics jumps 50% after upsized IPO, signaling renewed biotech IPO momentum.

SCRI LLY

🌍 US Read More →

📰News 📈 Stocks

Scribe Raises $128.7M in Upsized IPO Backed by Eli Lilly

July 24, 2026 (64 days ago)

Scribe Therapeutics, backed by Eli Lilly, raised $128.7 million in an upsized IPO, reflecting strong investor demand for biotech firms with major…

SCRIBE LLY

🌍 US Read More →

📰News 📈 Stocks

Biotech IPOs Outperform AI Listings, Lead US Stock Rally in 2026

July 21, 2026 (66 days ago)

Biotech IPOs lead US markets in 2026, outpacing AI listings as healthcare innovation takes center stage over artificial intelligence.

IBB SPX AIQ

🌍 US Read More →

📰News 📈 Stocks

Eli Lilly-backed Scribe Therapeutics files for $107.2 million IPO

July 20, 2026 (67 days ago)

Scribe Therapeutics, with Eli Lilly’s backing, files for a $107.2 million IPO, highlighting gene-editing sector momentum and potential biotech IPO revival.

LLY

🌍 US Read More →